Menopause — MCQs

Menopause Indian Medical PG Practice Questions and MCQs

Question 11: Which of the following drugs is NOT used for postmenopausal symptoms?

A. Conjugated estrogens
B. Tibolone
C. Alendronate
D. Danazol (Correct Answer)

Explanation: **Explanation:** The correct answer is **Danazol**. **1. Why Danazol is the correct answer:** Danazol is a synthetic steroid with strong **androgenic** and anti-estrogenic properties. It suppresses the pituitary-ovarian axis by inhibiting GnRH release. It is primarily used to treat **endometriosis**, fibrocystic breast disease, and hereditary angioedema. Because it induces a hypoestrogenic state, it can actually *cause* or worsen menopausal symptoms (like hot flashes and vaginal dryness) rather than treating them. **2. Why the other options are incorrect:** * **Conjugated Estrogens (Option A):** This is the gold standard for Hormone Replacement Therapy (HRT). It effectively treats vasomotor symptoms (hot flashes) and urogenital atrophy by replacing the declining endogenous estrogen. * **Tibolone (Option B):** A synthetic steroid with estrogenic, progestogenic, and androgenic properties. It is specifically used for postmenopausal symptoms and prevention of osteoporosis, particularly in women who wish to avoid withdrawal bleeding. * **Alendronate (Option C):** A bisphosphonate used to treat **postmenopausal osteoporosis**. While it doesn't treat vasomotor symptoms, it is a standard drug used to manage the long-term skeletal complications of menopause. **3. NEET-PG High-Yield Pearls:** * **First-line for Vasomotor Symptoms:** HRT (Estrogen + Progesterone if the uterus is intact; Estrogen alone if post-hysterectomy). * **Non-Hormonal Treatment:** SSRIs (e.g., Paroxetine), SNRIs (e.g., Venlafaxine), and Gabapentin are used for hot flashes in patients where HRT is contraindicated (e.g., breast cancer). * **Danazol Side Effects:** Hirsutism, acne, weight gain, and deepening of voice (due to androgenic activity).

Question 12: Premature menopause is defined as menopause occurring before which age?

A. 55 years
B. 50 years
C. 45 years (Correct Answer)
D. 40 years

Explanation: **Explanation:** The correct answer is **C. 45 years**. **Medical Concept:** Menopause is the permanent cessation of menstruation due to the loss of ovarian follicular activity. In the Indian context, the average age of menopause is approximately 47–48 years (globally around 51 years). **Premature Menopause** is clinically defined as the cessation of menses occurring between the ages of **40 and 45 years**. It affects approximately 5% of the female population. **Analysis of Options:** * **A & B (55 and 50 years):** These fall within the range of "Late Menopause" (after age 55) or the normal expected age for menopause. * **D (40 years):** This is a common point of confusion. Menopause occurring **before age 40** is specifically termed **Premature Ovarian Insufficiency (POI)** or Premature Ovarian Failure (POF). While "premature" in a general sense, the standard diagnostic threshold for POI is <40 years, whereas "Premature Menopause" covers the 40–45 age bracket. **NEET-PG High-Yield Pearls:** 1. **Premature Ovarian Insufficiency (POI):** Defined by amenorrhea, hypoestrogenism, and elevated gonadotropins (**FSH > 40 IU/L**) occurring before age 40. 2. **Most Common Cause:** While most cases are idiopathic, the most common identifiable chromosomal cause is **Turner Syndrome (45, XO)**. 3. **Smoking:** It is the most significant modifiable risk factor that can shift the age of menopause earlier by 1.5 to 2 years. 4. **Diagnosis:** Menopause is a retrospective clinical diagnosis made after **12 consecutive months** of amenorrhea.

Question 13: Estrogen deficiency leads to:

A. Postmenopausal bleeding
B. Decreased risk of cardiovascular diseases
C. Osteoporosis (Correct Answer)
D. Dysmenorrhea

Explanation: **Explanation:** The correct answer is **C. Osteoporosis**. **Why it is correct:** Estrogen plays a critical role in bone metabolism by inhibiting bone resorption. It promotes the apoptosis of osteoclasts (cells that break down bone) and stimulates osteoblast activity. Following menopause, the decline in estrogen levels leads to an accelerated phase of bone loss. This results in decreased bone mineral density (BMD) and architectural deterioration, significantly increasing the risk of fragility fractures. **Why the other options are incorrect:** * **A. Postmenopausal bleeding:** This is typically caused by endometrial atrophy (due to low estrogen) or, more concerningly, endometrial hyperplasia/carcinoma (usually due to *excess* or unopposed estrogen). Estrogen deficiency itself causes dryness and atrophy, not active bleeding. * **B. Decreased risk of cardiovascular diseases:** Estrogen is cardioprotective; it improves lipid profiles (increases HDL, decreases LDL) and promotes vasodilation. Therefore, estrogen deficiency *increases* the risk of atherosclerosis and coronary heart disease. * **D. Dysmenorrhea:** This refers to painful menstruation, which is mediated by prostaglandins during active cycles. Since estrogen deficiency occurs during menopause (cessation of cycles), dysmenorrhea disappears. **High-Yield NEET-PG Pearls:** * **Most common symptom of menopause:** Hot flashes (Vasomotor symptoms). * **Most common fracture site post-menopause:** Distal radius (Colles’ fracture) occurs early; Vertebral fractures are the most common overall; Hip fractures carry the highest morbidity. * **Gold standard for diagnosis:** DEXA Scan (T-score ≤ -2.5 indicates osteoporosis). * **Hormonal marker:** FSH > 40 IU/L is diagnostic of menopause.

Question 14: Which of the following statements regarding hormone status in menopausal women is false?

A. Decreased FSH (Correct Answer)
B. Increased LH
C. Decreased estrogen
D. Decreased progesterone

Explanation: **Explanation:** The hallmark of menopause is the depletion of ovarian follicles, leading to a significant decline in ovarian hormone production. This triggers a physiological feedback loop that is crucial for NEET-PG preparation. **1. Why Option A is the Correct (False) Statement:** In menopause, the primary event is the **decrease in Estrogen and Inhibin** (specifically Inhibin B). Under normal physiological conditions, these hormones exert negative feedback on the pituitary gland. When their levels drop, the negative feedback is removed, causing the pituitary to secrete **increased amounts of Follicle Stimulating Hormone (FSH)**. Therefore, FSH levels are **elevated** (typically >40 mIU/mL), not decreased. **2. Analysis of Incorrect Options:** * **Option B (Increased LH):** Similar to FSH, Luteinizing Hormone (LH) increases due to the loss of negative feedback from estrogen. While both rise, the rise in FSH is more pronounced and occurs earlier because its renal clearance is slower. * **Option C (Decreased Estrogen):** This is true. The cessation of follicular development leads to a drastic drop in Estradiol (E2). The predominant estrogen in menopause becomes **Estrone (E1)**, produced via peripheral aromatization of androstenedione in adipose tissue. * **Option D (Decreased Progesterone):** This is true. Since ovulation no longer occurs, the corpus luteum does not form, leading to a near-total absence of progesterone. **High-Yield Clinical Pearls for NEET-PG:** * **Gold Standard Diagnostic Marker:** Elevated **FSH** (>40 mIU/mL) is the most reliable biochemical marker for menopause. * **Inhibin B:** A decline in Inhibin B is one of the earliest markers of a declining ovarian reserve. * **Estrogen Shift:** Pre-menopause = Estradiol (E2); Post-menopause = Estrone (E1). * **LH/FSH Ratio:** In menopause, the ratio reverses, and FSH becomes higher than LH.

Question 15: In menopause, which of the following is not typically observed?

A. FSH (Correct Answer)
B. Cholesterol
C. Androgen
D. Cholesterol

Explanation: **Explanation:** In menopause, the primary physiological change is the depletion of ovarian follicles, leading to a significant decrease in estrogen and inhibin levels. This loss of negative feedback on the pituitary gland results in a **marked increase in Follicle-Stimulating Hormone (FSH)** levels. Therefore, a decrease in FSH is **not** observed; rather, an elevation (typically >40 mIU/mL) is the hallmark diagnostic feature. **Analysis of Options:** * **A. FSH (Correct):** As explained, FSH levels rise significantly due to the lack of ovarian feedback. A "decrease" or "lack of observation" of high FSH would be incorrect in a menopausal profile. * **B & D. Cholesterol:** Menopause is associated with an adverse lipid profile. Due to the loss of the cardioprotective effects of estrogen, there is typically an **increase** in Total Cholesterol and LDL, and a decrease in HDL. * **C. Androgen:** While adrenal androgens continue to be produced, overall ovarian androgen production (specifically androstenedione) **decreases** significantly after menopause, although the decline is less absolute than that of estrogen. **High-Yield NEET-PG Pearls:** * **Earliest biochemical marker** of ovarian aging: Decrease in **Inhibin B**. * **Most sensitive/diagnostic marker** for menopause: Elevated **FSH** (>40 mIU/mL). * **Estrogen shift:** The predominant estrogen changes from **Estradiol (E2)** (ovarian source) to **Estrone (E1)** (produced via peripheral conversion in adipose tissue). * **LH levels** also increase, but the FSH rise is more pronounced due to its longer half-life and the specific loss of inhibin.

Question 16: Hot flushes are observed due to deficiency of?

A. Estrogen (Correct Answer)
B. Progesterone
C. Testosterone
D. Cortisol

Explanation: **Explanation:** **1. Why Estrogen is the Correct Answer:** Hot flushes (vasomotor symptoms) are the most common symptom of the perimenopausal and menopausal transition. They occur due to the **decline in circulating estrogen levels**. Estrogen plays a critical role in stabilizing the **thermoregulatory center** in the hypothalamus. When estrogen levels drop, the "thermostat" becomes hypersensitive, narrowing the thermoneutral zone. This leads to an exaggerated heat-dissipation response (peripheral vasodilation and sweating) even with minor changes in core body temperature. **2. Why Other Options are Incorrect:** * **Progesterone:** While progesterone levels also decline during menopause, its primary role is in endometrial regulation. Progesterone withdrawal does not trigger the hypothalamic thermoregulatory dysfunction responsible for hot flushes. * **Testosterone:** Androgen levels decline gradually with age (senescence) rather than abruptly at menopause. Deficiency is more closely linked to decreased libido and muscle mass, not vasomotor instability. * **Cortisol:** Cortisol is a stress hormone produced by the adrenal cortex. Its deficiency (Addison’s disease) causes hypotension and electrolyte imbalances, not menopausal hot flushes. **3. NEET-PG High-Yield Pearls:** * **Most common symptom of menopause:** Hot flushes (75-80% of women). * **Hormonal Hallmark:** Decreased Estrogen + **Increased FSH** (FSH >40 IU/L is diagnostic of menopause). * **Mechanism:** Narrowing of the "Thermoreutral Zone" in the hypothalamus. * **Treatment of Choice:** Hormone Replacement Therapy (HRT) with Estrogen is the most effective treatment for vasomotor symptoms. * **Non-hormonal alternative:** SSRIs (e.g., Paroxetine) or Gabapentin are used if HRT is contraindicated.

Question 17: Hormone replacement therapy in post-menopausal women increases the risk of all the following conditions EXCEPT:

A. Breast cancer
B. Stroke
C. Colorectal cancer (Correct Answer)
D. Thromboembolism

Explanation: **Explanation:** The question focuses on the findings of the **Women’s Health Initiative (WHI) trial**, which redefined the risks and benefits of Hormone Replacement Therapy (HRT). **Why Colorectal Cancer is the correct answer:** HRT (specifically combined Estrogen and Progesterone) has a **protective effect** against colorectal cancer. Large-scale clinical trials demonstrated a significant reduction (approximately 30-40%) in the incidence of colorectal cancer among women using combined HRT. Therefore, it does not increase the risk; it decreases it. **Analysis of Incorrect Options:** * **Breast Cancer:** Long-term use of combined HRT (Estrogen + Progestogen) is associated with an increased risk of breast cancer. This risk is primarily linked to the progestogen component. * **Stroke:** HRT increases the risk of ischemic stroke. This is part of the overall cardiovascular risk profile associated with oral estrogen therapy in older post-menopausal women. * **Thromboembolism:** Oral estrogen increases the synthesis of clotting factors in the liver (first-pass effect), leading to a 2-to-3-fold increased risk of **Deep Vein Thrombosis (DVT)** and **Pulmonary Embolism**. **NEET-PG High-Yield Pearls:** 1. **Endometrial Cancer:** Unopposed estrogen therapy increases the risk of endometrial cancer; hence, Progesterone is always added if the uterus is intact. 2. **Fracture Risk:** HRT is highly effective in reducing the risk of **osteoporotic fractures** (hip and spine). 3. **Lipid Profile:** HRT typically increases HDL and decreases LDL, but it also increases **Triglycerides**. 4. **Gallstones:** HRT increases the risk of cholelithiasis due to increased cholesterol saturation of bile. 5. **Window of Opportunity:** HRT is safest when started within 10 years of menopause or before age 60.

Question 18: A 48-year-old female with severe dysfunctional uterine bleeding (DUB) underwent hysterectomy and wishes to take hormone replacement therapy. Physical examination, including breast examination, is normal, but X-ray shows osteoporosis. What is the treatment of choice?

A. Progesterone
B. Estrogen and progesterone
C. Estrogen (Correct Answer)
D. None

Explanation: ### **Explanation** The core principle in Hormone Replacement Therapy (HRT) is determining the presence of a uterus. **1. Why Estrogen is the Correct Answer:** The patient has undergone a **hysterectomy**. In women without a uterus, **Estrogen-only therapy (ERT)** is the treatment of choice. Estrogen effectively manages vasomotor symptoms and is highly effective in preventing and treating **osteoporosis** (as seen in this patient) by inhibiting osteoclast activity and reducing bone resorption. Since the uterus has been removed, there is no risk of estrogen-induced endometrial hyperplasia or carcinoma. **2. Why Other Options are Incorrect:** * **Progesterone (A):** Progesterone is not used as a standalone therapy for postmenopausal symptoms or osteoporosis. Its primary role in HRT is to protect the endometrium. * **Estrogen and Progesterone (B):** This "Combined HRT" is mandatory for women with an **intact uterus**. Adding progesterone to this specific patient is unnecessary and increases the risk of breast cancer and cardiovascular side effects without any clinical benefit, as she no longer has an endometrium to protect. * **None (D):** Treatment is indicated because the patient is symptomatic and has radiographic evidence of osteoporosis. ### **Clinical Pearls for NEET-PG:** * **Gold Standard for Osteoporosis:** While HRT is effective, **Bisphosphonates** are the first-line non-hormonal treatment for osteoporosis. However, if a postmenopausal woman is also symptomatic, HRT is an excellent choice. * **The "Uterus Rule":** * Uterus Present = Estrogen + Progesterone (to prevent endometrial CA). * Uterus Absent = Estrogen Only. * **Contraindications to HRT:** Undiagnosed vaginal bleeding, estrogen-dependent tumors (Breast/Endometrial CA), active thromboembolism (DVT/PE), and chronic liver disease. * **Window of Opportunity:** HRT is most beneficial when started within 10 years of menopause or before age 60.

Question 19: Which of the following is a common symptom indicated in menopausal women?

A. Hot flash (Correct Answer)
B. Breast cancer
C. Endometriosis
D. Uterine bleeding

Explanation: **Explanation:** **Correct Answer: A. Hot flash** Menopause is defined by the permanent cessation of menstruation due to the loss of ovarian follicular activity, leading to a profound decline in **estrogen** levels. This estrogen deficiency affects the thermoregulatory center in the hypothalamus (via increased neurokinin B and altered serotonin/norepinephrine levels), resulting in **vasomotor symptoms (VMS)**. Hot flashes are the most common and characteristic symptom of menopause, affecting approximately 75–85% of women. **Analysis of Incorrect Options:** * **B. Breast cancer:** While the risk of breast cancer increases with age and prolonged exposure to hormones (HRT), it is a pathological condition (malignancy), not a physiological symptom of menopause. * **C. Endometriosis:** This is an estrogen-dependent condition. Since estrogen levels drop significantly during menopause, endometriosis typically regresses or improves after the climacteric. * **D. Uterine bleeding:** Menopause is defined by 12 months of amenorrhea. Any vaginal bleeding occurring after menopause is considered **Post-Menopausal Bleeding (PMB)** and is a red flag that must be investigated to rule out endometrial carcinoma. **NEET-PG High-Yield Pearls:** 1. **Most common symptom:** Hot flashes (Vasomotor symptoms). 2. **Earliest sign of perimenopause:** Shortening of the follicular phase (decreased cycle length). 3. **Hormonal Hallmark:** Elevated **FSH >40 IU/L** is the most sensitive diagnostic marker for menopause. 4. **Treatment of choice:** Hormone Replacement Therapy (HRT) is the gold standard for vasomotor symptoms. If HRT is contraindicated, **SSRIs/SNRIs** or the newer **NK3 receptor antagonists (Fezolinetant)** are used.

Question 20: What is the average age of menopause?

A. 45 years
B. 47 years
C. 49 years
D. 51 years (Correct Answer)

Explanation: **Explanation:** **1. Understanding the Correct Answer (D):** Menopause is defined retrospectively as the permanent cessation of menstruation following the loss of ovarian follicular activity, confirmed after 12 consecutive months of amenorrhea. Globally, and specifically in Western data frequently cited in standard textbooks (like Williams Gynecology), the **average age of menopause is 51 years**. This timing is genetically predetermined and is primarily dictated by the depletion of the ovarian follicle pool. **2. Analysis of Incorrect Options:** * **A (45 years):** While menopause can occur at 45, it is considered early. Menopause occurring between ages 40–45 is termed "Early Menopause." * **B & C (47 & 49 years):** Although the average age of menopause in Indian women is often cited as slightly lower (around 47–48 years) in regional studies, for the purpose of standardized national exams like NEET-PG, the globally accepted standard of **51 years** remains the definitive answer unless "Indian context" is specifically mentioned. **3. High-Yield Clinical Pearls for NEET-PG:** * **Premature Ovarian Insufficiency (POI):** Menopause occurring before the age of **40 years**. * **Determinants:** The age of menopause is **not** affected by the age of menarche, number of pregnancies, lactation, or use of oral contraceptives. * **Smoking:** This is the most significant modifiable factor; it can accelerate follicular depletion and shift menopause **1–2 years earlier**. * **Hormonal Profile:** The hallmark of menopause is a significant **rise in FSH (>40 IU/L)** and a decrease in Estradiol (<20 pg/mL). FSH is the most sensitive diagnostic marker. * **First Sign:** The earliest clinical sign of approaching menopause (perimenopause) is usually a **shortening of the follicular phase** (shorter menstrual cycles).

Practice by Chapter

Physiology of Menopause

Practice Questions

Perimenopausal Transition

Practice Questions

Menopausal Symptoms and Management

Practice Questions

Hormone Replacement Therapy

Practice Questions

Non-hormonal Management Options

Practice Questions

Osteoporosis Prevention and Management

Practice Questions

Cardiovascular Health in Menopause

Practice Questions

Urogenital Atrophy

Practice Questions

Psychological Aspects of Menopause

Practice Questions

Premature Menopause

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free

Menopause — MCQs

Menopause — MCQs

On this page

Practice by Chapter

Want unlimited practice?